– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated with Combination of Obicetrapib and…
CALGARY, Alberta, June 02, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA)…
Masimo CO2, O3 and Sedline measurements are now available on Philips high acuity MX750 & MX850 IntelliVue monitors Philips patient…
Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies…
D. Diaz CCPHP Dr. Diego Diaz Collaborates with Castle Connolly Private Health Partners to Create a Concierge Medical Program that…
LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens…
With the Glitz and Glamour of a 20s Speakeasy, the Gala Honoured the Achievements of Dr. Kevin Schwartzman and the…
As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression,…
Company approaching Phase 2 topline data readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing dose…
ST. LOUIS, May 23, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment…